This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ho, G. Y. F. Articles by Burk, R. D. Search for Related Content PubMed PubMed Citation Articles by Ho, G. Y. F. Articles by Burk, R. D.

Natural History of Human Papillomavirus Type 16 Virus-Like Particle Antibodies in Young Women

¹ Departments of Epidemiology and Population Health, ² Microbiology and Immunology, ³ Pediatrics, and Obstetrics and Gynecology and Women’s Health, Albert Einstein College of Medicine, Bronx, New York, and ⁴ Rutgers University Student Health Service, New Brunswick, New Jersey

Immunization with a vaccine of human papillomavirus (HPV) type 16 virus-like particles (VLPs) can reduce incidence of HPV-16 infection and its related cervical intraepithelial neoplasia. However, development of detectable antibodies to VLPs does not always occur after natural HPV infection. This study examined prospectively for seroconversion and duration of antibodies to HPV-16 VLPs and their associated host and viral factors. Six-hundred eight subjects were tested for HPV DNA biannually and for IgG and IgA antibodies to HPV-16 VLPs annually for 3 years. Both IgG and IgA antibodies to HPV-16 VLPs were predominantly type specific. Women with cervicovaginal HPV-16 infection were 8–10 times more likely to seroconvert than those with infection of HPV-16-related types. Among subjects who had an incident infection with HPV-16, a maximum of 56.7% became seropositive for IgG within 8.3 months and 37.0% had IgA within 14 months. Detectable seroconversion was a slow process that required sufficient antigenic exposure associated with either a high viral load (relative risk = 5.7 for IgG) or persistent infection of HPV-16 (relative risk = 3.4 for IgA). The median duration for both types of antibodies was 36 months. Antibodies could persist for a long period of time if the initial antibody levels were high or if there was continued antigenic exposure.

This article has been cited by other articles:

				I. Sabol, M. Salakova, J. Smahelova, M. Pawlita, M. Schmitt, N. M. Gasperov, M. Grce, and R. Tachezy Evaluation of Different Techniques for Identification of Human Papillomavirus Types of Low Prevalence J. Clin. Microbiol., May 1, 2008; 46(5): 1606 - 1613. [Abstract] [Full Text] [PDF]

				M. J. J. Fleury, A. Touze, S. de Sanjose, F. X. Bosch, J. Klaustermeiyer, and P. Coursaget Detection of Human Papillomavirus Type 31-Neutralizing Antibodies from Naturally Infected Patients by an Assay Based on Intracellular Assembly of Luciferase-Expressing Pseudovirions Clin. Vaccine Immunol., January 1, 2008; 15(1): 172 - 175. [Abstract] [Full Text] [PDF]

				G. M. Clifford, H.-R. Shin, J.-K. Oh, T. Waterboer, Y.-H. Ju, S. Vaccarella, W. Quint, M. Pawlita, and S. Franceschi Serologic Response to Oncogenic Human Papillomavirus Types in Male and Female University Students in Busan, South Korea Cancer Epidemiol. Biomarkers Prev., September 1, 2007; 16(9): 1874 - 1879. [Abstract] [Full Text] [PDF]

				N. Van de Velde, M. Brisson, and M.-C. Boily Modeling Human Papillomavirus Vaccine Effectiveness: Quantifying the Impact of Parameter Uncertainty Am. J. Epidemiol., April 1, 2007; 165(7): 762 - 775. [Abstract] [Full Text] [PDF]

				C.C.R. Ragin, F. Modugno, and S.M. Gollin The Epidemiology and Risk Factors of Head and Neck Cancer: a Focus on Human Papillomavirus J. Dent. Res., February 1, 2007; 86(2): 104 - 114. [Abstract] [Full Text] [PDF]

				D. Saslow, P. E. Castle, J. T. Cox, D. D. Davey, M. H. Einstein, D. G. Ferris, S. J. Goldie, D. M. Harper, W. Kinney, A.-B. Moscicki, et al. American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors CA Cancer J Clin, January 1, 2007; 57(1): 7 - 28. [Abstract] [Full Text] [PDF]

				M. M. Lipke An Armamentarium of Wart Treatments Clin. Med. Res., December 1, 2006; 4(4): 273 - 293. [Abstract] [Full Text] [PDF]

				J. J. Orozco, J. J. Carter, L. A. Koutsky, and D. A. Galloway Humoral Immune Response Recognizes a Complex Set of Epitopes on Human Papillomavirus Type 6 L1 Capsomers J. Virol., August 1, 2005; 79(15): 9503 - 9514. [Abstract] [Full Text] [PDF]